Table 1 from Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation
收藏数据链接：
官方服务：
资源简介：
EC50 for pERK and proliferation across tumor cell lines
创建时间：
2025-04-23
